CytomX Therapeutics (CTMX) Capital Expenditures Growth (3y) (2017 - 2025)
CytomX Therapeutics (CTMX) Capital Expenditures Growth (3y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -12.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.37% |
| Sep 30, 2025 | -32.19% |
| Jun 30, 2025 | -59.68% |
| Mar 31, 2025 | -45.52% |
| Dec 31, 2024 | -31.14% |
| Sep 30, 2024 | -58.61% |
| Jun 30, 2024 | -5.57% |
| Mar 31, 2024 | -51.08% |
| Dec 31, 2023 | 34.08% |
| Sep 30, 2023 | -77.38% |
| Jun 30, 2023 | 140.86% |
| Mar 31, 2023 | -64.23% |
| Dec 31, 2022 | -36.27% |
| Sep 30, 2022 | -44.37% |
| Jun 30, 2022 | 31.80% |
| Mar 31, 2022 | -26.25% |
| Dec 31, 2021 | 29.05% |
| Sep 30, 2021 | -47.41% |
| Jun 30, 2021 | -36.01% |
| Mar 31, 2021 | 35.93% |